MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria

Phase 3
Completed
Conditions
Proteinuria
Interventions
Drug: Placebo
First Posted Date
2014-09-05
Last Posted Date
2018-10-10
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
58
Registration Number
NCT02232763
Locations
🇰🇷

Seoul National University Children's Hospital, Seoul, Korea, Republic of

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy

Phase 4
Conditions
IgA Nephropathy
Interventions
Drug: Abelmoschus manihot
First Posted Date
2014-09-04
Last Posted Date
2016-07-06
Lead Sponsor
Chen Xiangmei
Target Recruit Count
1600
Registration Number
NCT02231125
Locations
🇨🇳

Guang An Men Hospital China Academy of Chinese Medical Sciences, Beijing, Beijing, China

🇨🇳

Jilin Province People's Hospital, Changchun, Jilin, China

🇨🇳

Ningxia Hui Autonomous Region's Hospital, Yinchuan, Ningxia, China

and more 85 locations

the Pharmacokinetic Profiles of Losartan With DW1029M

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DW1029M 1200mg and Losartan 50mg
First Posted Date
2014-08-08
Last Posted Date
2015-06-29
Lead Sponsor
Dong Wha Pharmaceutical Co. Ltd.
Target Recruit Count
12
Registration Number
NCT02212769
Locations
🇰🇷

Chonbuk National University Hospital, Jeonju, Jeollabukdo, Korea, Republic of

Residual Renal Function Preservation in Peritoneal Dialysis Patients

Not Applicable
Conditions
Chronic Renal Disease
Interventions
Drug: spirolactone
Other: blank control
First Posted Date
2014-07-15
Last Posted Date
2014-08-01
Lead Sponsor
Second Xiangya Hospital of Central South University
Target Recruit Count
96
Registration Number
NCT02190318

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

Phase 4
Completed
Conditions
Serious Mental Illness
Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Cardiovascular Disease
Major Depressive Disorder
Psychosis NOS
Interventions
First Posted Date
2014-07-11
Last Posted Date
2023-01-30
Lead Sponsor
Mclean Hospital
Target Recruit Count
227
Registration Number
NCT02188121
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
715
Registration Number
NCT02183701

Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

Phase 4
Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-06-24
Last Posted Date
2014-06-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
363
Registration Number
NCT02172586

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

Not Applicable
Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-04-23
Last Posted Date
2017-02-10
Lead Sponsor
Anthony J Viera, MD, MPH
Target Recruit Count
28
Registration Number
NCT02121041
Locations
🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

Phase 4
Conditions
Proteinuria
Glomerulonephritis
Interventions
Drug: Shenyankangfu tablets and Losartan potassium 100mg
Drug: Shenyankangfu tablets and Losartan potassium 50mg
First Posted Date
2014-02-14
Last Posted Date
2015-07-01
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
720
Registration Number
NCT02063100
Locations
🇨🇳

National Clinical Research Center for Kidney Disease, State Key Laboratory of Kidney Disease, Department of Nephrology, Chinese PLA General Hospital, Beijing, Beijing, China

🇨🇳

Beijing Friendship,Capital Medical University, Beijing, Beijing, China

🇨🇳

Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China

and more 40 locations

Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

Phase 2
Completed
Conditions
Fibrosis
Inflammation
Interventions
Drug: Matching placebo
First Posted Date
2014-01-30
Last Posted Date
2019-12-10
Lead Sponsor
Hennepin Healthcare Research Institute
Target Recruit Count
108
Registration Number
NCT02049307
Locations
🇺🇸

NIH Clinical Center, Bethesda, Maryland, United States

🇺🇸

UCSF, San Francisco, California, United States

🇺🇸

Hennepin County Medical Center, Minneapolis, Minnesota, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath